100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure

When you see the phrase insulin independence in a Type 1 diabetes headline, you can almost predict what comes next.

“Cure.”

The recent results from Eledon Pharmaceuticals using its anti-CD40L antibody, tegoprubart, in people receiving donor islet transplants are genuinely impressive. In early-phase data, all evaluable participants achieved sustained insulin independence.

For people living with recurrent severe hypoglycaemia despite optimised therapy, that is not theoretical progress. It is life-altering.

But it is not — yet — a cure for Type 1 diabetes.

And we can say that without diminishing what has been achieved. Because what has been achieved is a massive structural shift in how we treat the disease.

What Is Actually Happening Here?

The current trial at UChicago Medicine is not regenerating a person’s own beta cells. It is not reversing the autoimmune process that caused Type 1 diabetes in the first place.

Instead, it combines two interventions:

1. Transplantation of donor-derived pancreatic islets.
2. Tegoprubart, a next-generation immune-modulating therapy designed to protect those grafts.

Historically, islet transplantation has worked — but at a severe biological cost. Traditional immunosuppression relies heavily on calcineurin inhibitors such as tacrolimus. These carry profound toxicity risks and actively impair beta-cell function over time. You are essentially poisoning the cells you just transplanted.

Tegoprubart changes the math. It blocks the CD40L costimulatory pathway, a key signalling axis required for full immune activation. By interrupting CD40/CD40L interactions, the drug dampens T-cell and B-cell activation.

It stops the immune cascade that leads to graft rejection, without the toxic side effects.

The Human Data

The preliminary data reported by Eledon on the first six evaluable patients gives us actual human evidence to look at:

• 100% Success: All six patients achieved sustained insulin independence and zero severe hypoglycaemic episodes.
• Durability: The first three patients have remained entirely insulin-free for over a year.
• Glycaemic Control: Patients maintained HbA1c levels well below 6% (one as low as 5.3%) without exogenous insulin.
• Unprecedented Engraftment: Because tegoprubart is not toxic to beta cells, islet engraftment was estimated to be three to five times higher than in comparable patients receiving standard tacrolimus.

In short: the transplanted islets survive longer, engraft better, and function optimally.

That is meaningful progress in transplant immunology.

The Two Immune Walls

At Diabettech, we’ve discussed this before: Type 1 diabetes presents two separate immune problems.

The first is classic transplant rejection — the immune system attacking foreign tissue. Tegoprubart clearly addresses this wall.

The second is autoimmune memory — the immune system’s learned targeting of beta-cell antigens. That process begins years before diagnosis and persists long after. Preclinical data in autoimmune models suggest that blocking CD40L might reduce pathological T-cell activation. In theory, tegoprubart could soften aspects of the underlying autoimmune process.

But “might” is doing a lot of heavy lifting in that sentence.

Until we see durable, antigen-specific immune tolerance without life-long systemic immune therapy, we cannot call this a cure. A cure implies the disease process is permanently neutralised.

The US Regulatory Distraction: Why the Islet Cell Act Isn’t the Answer

If you follow US diabetes advocacy, you’ve likely seen the push for the “Islet Cell Act.”

Right now, the FDA regulates deceased-donor pancreatic islets as biologic drugs, requiring a massive, expensive Biologics License Application (BLA). In contrast, countries like the UK, Canada, and Australia regulate them as organs for transplant.

The FDA’s stance means donor islets in the US (like Lantidra) are commercialised, aggressively expensive, and restricted to a tiny fraction of patients. The Islet Cell Act seeks to change this, reclassifying donor islets as organs so academic transplant centres can actually use them without acting like pharma companies.

Eledon’s current trial relies entirely on these deceased-donor islets.

So, fixing the FDA’s regulatory bottleneck seems like the obvious next step to get Eledon’s breakthrough to the masses, right?

Wrong.

The Islet Cell Act is a necessary fight for the immediate future. It would make life-saving therapy accessible for the small subset of patients with severe, life-threatening hypoglycaemia unawareness.

But as a macro-level cure strategy? It doesn’t solve the math.

Even if you strip away the FDA’s red tape and make donor islets perfectly accessible, we run headfirst into a brutal biological reality: there are simply not enough deceased organ donors to treat the millions of people living with Type 1 diabetes.

You cannot scale a cadaver-dependent therapy.

The Scalable Blueprint of a Cure

This is why Eledon’s true value isn’t tied to the donor islets it is currently testing. Its real value is what happens when you combine it with the next generation of cells.

The field has finally moved away from the idea of a single “moonshot” miracle. A true functional cure is going to be an engineered protocol — a combination therapy stack.

We now have human evidence for the different components of this stack:

• The Cells: Vertex Pharmaceuticals proved that stem-cell-derived islets can effectively replace lost beta cells at scale.
• Immune Evasion: Sana Biotechnology is testing hypoimmune engineering to hide those cells.
• Autoimmune Modulation: NextCell’s ProTrans has shown that the autoimmune environment can be durably reshaped for years.

Eledon fits perfectly into this emerging blueprint. Right now, it solves the toxicity problem of transplant rejection. But in the future, it acts as the crucial “immune stability” layer in a combination therapy.

In fact, Sernova Biotherapeutics is already collaborating with Eledon to pair tegoprubart with its implantable Cell Pouch and endlessly scalable stem-cell-derived islets.

If we can combine a scalable supply of lab-grown beta cells with an immunosuppression regimen that actually protects them without causing systemic toxicity, we bypass the donor shortage entirely. We render the FDA’s cadaveric regulatory bottleneck obsolete.

What Do We Think?

The correct response to the Eledon data is not scepticism. And it is not the unchecked euphoria we’ve seen recently.

It is measured optimism.

We are getting exponentially better at protecting replacement beta cells. We are learning how to modulate immune pathways precisely. We are actively dismantling the toxicity barriers that once made transplantation untenable.

What we are seeing today is not the final architecture. It is a load-bearing pillar being put into place.

That is how real cures are built — layer by layer.

Eledon’s results move the field forward. They do not yet end Type 1 diabetes. And recognising that difference is how we stay both hopeful and honest, and avoid the “5 years” trap.